May 22, 2023

MultiplexDX reached a significant milestone and signed a Memorandum with Oncology Institute in Kosice

MultiplexDX joined the conference organized by the Eastern Slovak Institute of Oncology in Kosice on the 20th anniversary of its establishment.

Our CEO, Pavol Cekan, and the CEO of the Eastern Slovak Institute of Oncology, Tomas Sieber, agreed on strengthening cooperation in providing better health care and medical procedures for cancer patients and improving research, development, and education for oncologists.

As a part of the conference, we represented our innovative diagnostic technology and the latest data on more accurate diagnostic tests for breast cancer patients we work on at MultiplexDX.

Thank you for your warm welcome and other distinguished guests at the conference!

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News